AHCO AdaptHealth Corp.
Services-Home Health Care Services · Nasdaq · SEC CIK 1725255 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY6.3%
TTM net income YoY-594.6%
TTM EPS YoY-632.1%
Revenue 3-yr CAGR0.3%
Net income 3-yr CAGR—
Margins
Gross margin15.9%
Operating margin-11.5%
Net margin-12.9%
FCF margin2.6%
EBITDA margin2.2%
Returns
ROE-28.6%
ROA-9.5%
ROIC (approx.)-8.9%
Asset turnover0.73x
Leverage & solvency
Liabilities / assets70.6%
Debt / equity1.54x
Current ratio1.13x
Interest coverage—
Cash quality & payout
Operating cash flow / net income-1.42x
Accruals ratio-23.0%
Payout ratio—
Capex / revenue15.8%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $3.24B | $3.26B |
| Cost of revenue | $2.64B | $2.58B |
| Gross profit | $609.20M | $681.09M |
| SG&A expense | $382.29M | $359.24M |
| Operating income | $90.87M | $263.73M |
| Interest expense | $103.60M | $124.70M |
| Pretax income | -$15.15M | $136.02M |
| Income tax | $50.88M | $41.24M |
| Net income | -$70.79M | $90.42M |
| EBITDA | $472.80M | $629.07M |
| EPS (basic) | -0.52 | 0.62 |
| EPS (diluted) | -0.52 | 0.61 |
| Weighted avg. shares (diluted) | 135.15M | 135.53M |
| Balance sheet | ||
| Cash & equivalents | $106.14M | $109.75M |
| Receivables | $370.90M | $408.02M |
| Inventory | $114.89M | $139.84M |
| Current assets | $728.90M | $755.79M |
| PP&E, net | $503.19M | $474.56M |
| Goodwill | $2.46B | $2.68B |
| Intangibles | $35.77M | $105.55M |
| Total assets | $4.32B | $4.49B |
| Current liabilities | $712.39M | $566.99M |
| Short-term debt | $20.31M | $16.25M |
| Long-term debt | $1.72B | $1.96B |
| Total debt | $1.74B | $1.98B |
| Total liabilities | $2.79B | $2.91B |
| Shareholders' equity | $1.52B | $1.57B |
| Net debt | $1.63B | $1.87B |
| Shares outstanding | 135.45M | 134.60M |
| Cash flow statement | ||
| Operating cash flow | $601.77M | $541.84M |
| Capital expenditure | $382.39M | $306.06M |
| Free cash flow | $219.38M | $235.78M |
| Investing cash flow | -$303.19M | -$310.27M |
| Financing cash flow | -$302.19M | -$198.95M |
| Depreciation & amortization | $381.93M | $365.33M |
| Stock-based compensation | $21.88M | $14.88M |
| Share buybacks | $0 | $0 |
Free plan shows the latest 2 periods; Pro shows all 8 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.